News Releases

Date Title
12/22/2016 Summary ToggleEnanta Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
12/19/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Submission of NDA for Investigational, Pan-Genotypic HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Genotypes 1 through 6 of Chronic Hepatitis C Virus (HCV)
11/22/2016 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Dr. Lesley Russell to Its Board of Directors
11/21/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016
11/15/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
11/11/2016 Summary ToggleEnanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C
11/11/2016 Summary ToggleEnanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2016
11/01/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016
10/26/2016 Summary ToggleEnanta Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference
10/03/2016 Summary ToggleEnanta Pharmaceuticals Announces New Data Presentations at The Liver Meeting® 2016